Targeting galactose metabolic reprogramming overcomes immunotherapy resistance in KRAS-mutant lung adenocarcinoma: Integrative multi-omics and machine learning approaches.
BACKGROUND: KRAS-mutant lung adenocarcinoma (LUAD) is associated with aggressive phenotypes and therapy resistance, which highlights an urgent need to identify reliable biomarkers and therapeutic targets. A prognostic model integrating GM-related genes demonstrated superior predictive performance.
BACKGROUND: KRAS-mutant lung adenocarcinoma (LUAD) is associated with aggressive phenotypes and therapy resistance, which highlights an urgent need to identify reliable biomarkers and therapeutic targets. A prognostic model integrating GM-related genes demonstrated superior predictive performance.
What the study was
- Study design
- Cohort study
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Translational oncology
Why it surfaced
Relevant Novel therapeutics: immunotherapy, CAR-T, targeted therapy study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.